

CURRICULUM VITAE

STEVEN J. HOLTZ, M.D.

February 2004

Date of Birth: November 29, 1950

Place of Birth: New York, New York

Addresses:

130 La Casa Via
Building 2, Suite 206
Walnut Creek, California 94598
Phone: (925) 939-9400
Fax: (925) 939-1819
Email: sjh182@aol.com

2485 High School Avenue
Suite 112
Concord, California 94520
Phone: (925) 827-2627

American Boards:

Diplomate, American Board of Psychiatry and Neurology (Neurology), 1981

Diplomate, National Board of Medical Examiners, 1975

Academic Appointments:

Associate Clinical Professor of Neurology
University of California School of Medicine,
San Francisco
1999 - present

Assistant Clinical Professor of Neurology
University of California School of Medicine,
San Francisco
1981 - 1999

CURRICULUM VITAE

Steven J. Holtz, M.D.

Executive Board Member
President-Elect
Association of the Clinical Faculty
University of California School of Medicine - San Francisco
2004

Executive Board Member
Secretary
Association of the Clinical Faculty
University of California School of Medicine - San Francisco
2003

Executive Board Member
Treasurer
Association of the Clinical Faculty
University of California School of Medicine - San Francisco
2002

Neurology Clinical Faculty Representative
Association of the Clinical Faculty
University of California School of Medicine - San Francisco
1999 – 2001

Assistant Clinical Professor of Neurology
University of California School of Medicine, Davis
1983 - 1999

Adjunct Assistant Professor of Neurology
Samuel Merritt College
Oakland, California
1990 – present

Clinical Preceptor
Health & Medical Apprenticeship Program
University of California, Berkeley
1985 - present

CURRICULUM VITAE

Steven J. Holtz, M.D.

Neurological Consultant
National Institute of Neurological and Communicative Disorders and Stroke
National Institutes of Health
Bethesda, Maryland
1986

Attending Physician/Consultant in Neurology
Veterans Administration Medical Center
Martinez, California
1980 - 1999

Teaching Fellow in Neurology
Boston University School of Medicine
1976 - 1979

Education:

Boston University, Boston, Massachusetts, A.B. (cum laude), 1972

Boston University School of Medicine, M.D., 1974

Residencies and Internships:

Boston University Affiliated Hospitals Training Program in Neurology
Junior Assistant Resident in Neurology
Senior Assistant Resident in Neurology
Resident in Neurology
July 1976 - June 1979

Kaiser Foundation Hospital
Oakland, California
Internal Medicine
June 1975 - June 1976

CURRICULUM VITAE

Steven J. Holtz, M.D.

Kaiser Foundation Hospital
Oakland, California
Internship in Internal Medicine
June 1974 - June 1975

Professional Associations:

Fellow - American Academy of Neurology
1989 - present

Member - American Academy of Neurology
1976 - present

Member - Legal Affairs Sub-committee
American Academy of Neurology
1992 – present

Member - American College of Physicians
1980 - 1995

Member - American Society of Neurorehabilitation
1992 - present

Professional Appointments:

Chairman - Medical Advisory Board
Epilepsy Foundation of Northern California
1992 - 1999
Member - 1987 - present

Fellow - Stroke Council
American Heart Association
1991 - present

Member - Medical Advisory Board
Multiple Sclerosis Society - Northern California Chapter
1988 - present

CURRICULUM VITAE

Steven J. Holtz, M.D.

Member - Medical Advisory Board
Easter Seal Society of the Bay Area
1998 - 2000

Member - Medical Advisory Board
Stroke Support Group of Contra Costa County
Walnut Creek and Concord, California
1983 - present

Member - National Stroke Association
1992 - present

Member - Neurology Advisory Committee
Kentfield Rehabilitation Hospital
Kentfield, California
1991 - 1998

Qualified Medical Evaluator (QME)
State of California
Industrial Medical Council
QME No. 003060
1991 - present (Inactive)

Member - Neurology Panel
Commission on Peace Officer Standards and Training
State of California - Department of Justice
1992

Medical Director
Alzheimer's Unit
Crestwood Treatment Center
Pleasant Hill, California
1988 - present

Medical Director
Manor Care
Arcadia Alzheimer's Special Care Unit
Walnut Creek, California
1998 - 2001

CURRICULUM VITAE

Steven J. Holtz, M.D.

Medical Director
Brain Injury Program
Guardian of Concord
1996 - 1999

Medical Director for Neurology
Paradigm Health Corporation
1001 Galaxy Way, Suite 300
Concord, CA 94520
1996 - 1999

Neurorehabilitation Consultant
Golden State Rehabilitation Hospital
San Ramon, California
1989 - 1995

Neurorehabilitation Consultant
Contra Costa Rehabilitation Center
Pittsburg, California
1993 - 1994

Medical Director
Neurocare, Inc.
Rehab Without Walls
Concord, California
1993

Medical Director
Stroke Rehabilitation Program
Golden State Rehabilitation Hospital
San Ramon, California
1989 - 1993

Medical Staff President
Golden State Rehabilitation Hospital
San Ramon, California
1990 - 1992

CURRICULUM VITAE

Steven J. Holtz, M.D.

Medical Director
Alzheimer's Disease Program
Mt. Diablo Rehabilitation Center
Pleasant Hill, California
1985 - 1989

Medical Director
Head Injury Program
Mt. Diablo Rehabilitation Center
1983 - 1986

Hospital Affiliations:

John Muir Medical Center
Walnut Creek, CA

Mt. Diablo Medical Center
Concord, CA

Kaiser Foundation Hospital
Walnut Creek, CA

The Medical Center at the
University of California, San Francisco
San Francisco, California

Veterans Administration
Northern California System of Clinics
Pleasant Hill, CA

Licensure:

California #G30609, 1975 - present
Massachusetts #40313, 1976-1979

CURRICULUM VITAE

Steven J. Holtz, M.D.

Professional Organizations:

American Academy of Neurology (1976 - present)
American College of Physicians (1975 - 1995)
California Medical Association (1979 - present)
Alameda-Contra Costa Medical Association
(1979 - present)
San Francisco Neurological Association (1980 - present)
American College of Legal Medicine (1992 - 1998)

Awards:

University of California School of Medicine,
San Francisco
Outstanding Teacher in Clinical Preceptorship
(1987, 1988, 1989, 1992)

Major Course Presentations:

Course Director

The Neurologist as An Expert Witness
50th Anniversary Meeting
The American Academy of Neurology
Minneapolis, Minnesota
May 1998

Course Director

The Neurologist as An Expert Witness
51st Annual Meeting
The American Academy of Neurology
Toronto, Ontario, Canada
April 1999

CURRICULUM VITAE

Steven J. Holtz, M.D.

Course Director

The Neurologist as An Expert Witness
52nd Annual Meeting
The American Academy of Neurology
San Diego, California
May 2000

Course Director

The Neurologist as An Expert Witness
53rd Annual Meeting
The American Academy of Neurology
Philadelphia, Pennsylvania
May 2001

Course Director

The Neurologist as An Expert Witness
54th Annual Meeting
The American Academy of Neurology
Denver, Colorado
April 2002

Special Professional Interests and Expertise:

Head Injuries, Nerve Injuries, Seizure Disorders, Alzheimer's Disease and other Dementias, Stroke, Neurological Rehabilitation, Multiple Sclerosis, Headache, Parkinson's Disease

Numerous lectures given to professional and lay audiences regarding these topics.

Publications and References:

Gammopathy with proximal motor axonopathy simulating motor neuron disease, NEUROLOGY 1986; 36:273-276

CURRICULUM VITAE

Steven J. Holtz, M.D.

PERIPHERAL AND CRANIAL NERVE INJURY DUE TO TRAUMA,
American Jurisprudence Proof of Facts, 3d Series, Volume 10, 1990,
Lawyers Cooperative Publishing.

NERVE INJURY FROM EXPOSURE TO TOXIC METALS,
American Jurisprudence Proof of Facts, 3d Series, Volume 14, 1991,
Lawyers Cooperative Publishing.

NERVE INJURY FROM EXPOSURE TO DRUGS, American Jurisprudence
Proof of Facts, 3d Series, Volume 15, 1992, Lawyers Cooperative
Publishing.

NERVE INJURY FROM EXPOSURE TO INDUSTRIAL AGENTS,
American Jurisprudence Proof of Facts, 3d Series, Volume 16, 1992,
Lawyers Cooperative Publishing.

Research Activities:

PRINCIPAL INVESTIGATOR

An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg bid. (3 mg/day) through 6 mg bid.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting," 1997 – 1999.

SUBINVESTIGATOR

"Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO), Phase III," 1999 - present .

"A Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23F2G (LeukArrest ?) in Patients with Acute Ischemic Stroke," 1999 – 2000.

"The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer's Disease," 1999 – present.

CURRICULUM VITAE

Steven J. Holtz, M.D.

Lamictal? in Combination with Newer and Older Antiepileptic Drugs and as Mono-therapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: Trial to Assess and Refine Global Epilepsy Treatment)," 1999 – present.

Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures," 1998 – present.

"Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy," 1998 – 2000.

"A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Prosaptide When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus," 1998 – 1999.

Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Multi-center Study in Patients with Partial Seizures," 1998 – 1999.

The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group Multinational, Multi-center Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke.,"1997 – present.

The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage," 1997 – 1999.

The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, 1997 – 1999 Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke."

"Enlimomab Acute Stroke Study, Phase III," 1995 – 1996.

"DHE 454 Migraine Study, Phase III." 1995.

CURRICULUM VITAE

Steven J. Holtz, M.D.

A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity, 2002.

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanriole versus Placebo or Ropinerole in Patients with Early Parkinson's Disease, 2002 – present.

Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-666E, 2002 – present.

Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A randomized, Double-Blind Study, With 18 Months Follow-up, 2001 - present

A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke, 2001 – 2002.

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke, 2001 – present.

Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo, 2001 – present.

Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson's Disease in Patients Treated with L-Dopa or Dopamine Agonist, 2001.

CURRICULUM VITAE

Steven J. Holtz, M.D.

Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain, 2001.

Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer's Disease, 2000 – 2002.

Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin©) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V), 2000 – present.